Hallet, Julie
Isenberg-Grzeda, Elie
Law, Calvin H. L.
Barabash, Victoria
Zuckerman, Jesse
Singh, Simron
Myrehaug, Sten D.
Assal, Angela
Chan, Wing C.
Coburn, Natalie G.
Mahar, Alyson L.
Funding for this research was provided by:
Canadian Institutes of Health Research
Article History
Received: 7 April 2022
Accepted: 16 September 2022
First Online: 5 October 2022
Declarations
:
: JH has received speaking honoraria from Ipsen Biopharmaceuticals and Advanced Accelerator Applications. EIG has a consulting agreement with Celgene USA CL has received speaking honoraria from Ipsen Biopharmaceuticals and Novartis Oncology. SS has received speaking honoraria from Ipsen Biopharmaceuticals Canada and Novartis Oncology, and research grants from Novartis Oncology and EMD Serono. NC receives salary support from Cancer Care Ontario as Lead for Patient-Reported Outcomes, and an honorarium from Astra-Zeneca. All remaining authors have declared no conflict of interest.